Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies

[1]  L. Soroceanu,et al.  Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies , 2019, British Journal of Cancer.

[2]  C. Ireson,et al.  The role of mouse tumour models in the discovery and development of anticancer drugs , 2019, British Journal of Cancer.

[3]  N. Hayward,et al.  Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma , 2018, Molecular oncology.

[4]  Levi A Garraway,et al.  MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas. , 2019, Cancer discovery.

[5]  Kyoung-Mee Kim,et al.  Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy , 2018, Nature Genetics.

[6]  Evert Bosdriesz,et al.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.

[7]  K. Crandall,et al.  Systematic pan-cancer analysis of somatic allele frequency , 2018, Scientific reports.

[8]  Krishna R. Kalari,et al.  Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study , 2017, Breast Cancer Research.

[9]  M. Hidalgo,et al.  Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  W. Bolosky,et al.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies , 2017, Proceedings of the National Academy of Sciences.

[11]  Rameen Beroukhim,et al.  Patient-derived xenografts undergo murine-specific tumor evolution , 2017, Nature Genetics.

[12]  H. Schaider,et al.  Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma , 2017, Oncotarget.

[13]  Adam A. Friedman,et al.  Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations , 2017, Clinical Cancer Research.

[14]  J. Buchner,et al.  The HSP90 chaperone machinery , 2017, Nature Reviews Molecular Cell Biology.

[15]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[16]  Myrtle Davis,et al.  Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies , 2017, Clinical Cancer Research.

[17]  Yulei N. Wang,et al.  A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) , 2016, Cancer.

[18]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[19]  D. Adams,et al.  BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts , 2016, Cell reports.

[20]  Scott E. Martin,et al.  Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.

[21]  M. Zauderer,et al.  Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2016, Clinical Cancer Research.

[22]  G. Mills,et al.  Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies , 2015, Clinical Cancer Research.

[23]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[24]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[25]  K. Jhaveri,et al.  Ganetespib: research and clinical development , 2015, OncoTargets and therapy.

[26]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[27]  I. Fichtner,et al.  A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option , 2015, International journal of cancer.

[28]  J. Huh,et al.  Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients , 2015, Oncotarget.

[29]  R. Fonseca,et al.  Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. , 2015, Blood.

[30]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[31]  Judy Lucas,et al.  Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. , 2014, Biochemical pharmacology.

[32]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.

[33]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[34]  D. Proia,et al.  Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib , 2014, Molecular Cancer Therapeutics.

[35]  Mohammad Fallahi-Sichani,et al.  Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.

[36]  K. Flaherty,et al.  The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling , 2013, PloS one.

[37]  F. Hodi,et al.  Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma , 2013, PloS one.

[38]  Yuhanis Yusof,et al.  A comparison of normalization techniques in predicting dengue outbreak , 2010 .

[39]  L. Poling,et al.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage , 2008, Pigment cell & melanoma research.

[40]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[41]  D. Schadendorf,et al.  Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated Melanoma , 2004, Oncology Research and Treatment.